Full-Time

Key Account Director

Life Sciences

Posted on 6/13/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

No salary listed

Senior, Expert

Company Historically Provides H1B Sponsorship

Remote in USA + 1 more

More locations: Philadelphia, PA, USA

Job can be performed in Philadelphia, PA or remotely.

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Minimum 10+ years in Business Development and Sales in the Life Sciences sector as lead account and relationship manager (Pharma / Biotech)
  • Bachelor degree in a Science or Business discipline; Advanced degree (MBA, PhD or Healthcare certification) desired
Responsibilities
  • Develop and Drive global account strategy in coordination with our scientific and business operations teams
  • Meet and exceed revenue goals for All Tempus product lines at the account while delivering on established strategic objectives for specific client accounts
  • Build and maintain executive and R&D relationships & drive our CXO strategy leveraging Tempus senior leadership
  • Become an expert in the partner’s strategy, pipeline and portfolio to proactively determine all areas that the Tempus platform could be leveraged for advancing innovation
  • Negotiate, secure and manage pull-through of contracts with assigned client accounts
  • Align the cross functional team of Product Specialists, Alliance Managers, Translational Researchers and Commercial Operations to most efficiently identify and deliver value at our clients
  • Partner with our clients to develop and announce impactful case studies leveraging the Tempus platform to advance precision medicine
  • Contribute to the development of the Life Sciences portfolio by providing feedback to Leadership regarding client responses and suggestions; maintain a solution-oriented mindset
  • Track progress against defined strategic objectives and revenue goals; review progress/setbacks frequently with broader Account Team and Tempus Leadership
  • Travel approximately 40% of working time, domestically and internationally
  • Other duties as assigned

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data, helping physicians make informed treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines AI with extensive research to provide tailored insights for both healthcare providers and drug developers, generating revenue through access to its platform and services.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Deep 6 AI expands Tempus' data network and precision medicine capabilities.
  • $560 million debt financing supports Tempus' growth and AI-driven healthcare solutions.
  • Collaboration with Artera enhances AI cancer test access, increasing Tempus' oncology influence.

What critics are saying

  • Integration challenges with Deep 6 AI could delay Tempus' expansion plans.
  • $560 million debt financing increases financial leverage, posing risk if revenue growth lags.
  • Exclusive partnership with Artera may limit Tempus' collaboration opportunities in prostate testing.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids drug development by discovering novel targets and evaluating treatments.
  • Tempus' pan-cancer organoid platform enhances personalized therapeutic opportunities for cancer patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Life Care News
Mar 30th, 2025
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

Tempus exhibits 4 abstracts at the 2025 American College of Cardiology Annual Meeting.

Tempus
Mar 12th, 2025
Tempus Announces Acquisition of Deep 6 AI | Tempus AI

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO --(BUSINESS WIRE)--Mar. 11, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision

TipRanks
Mar 12th, 2025
Tempus AI (TEM) Strengthens Precision Medicine with Deep 6 AI Deal, Cathie Wood Buys the Dip

Tempus AI has acquired Deep 6 AI to expand its reach and enhance offerings in precision medicine.

Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

INACTIVE